Trials
TUSTIN, CA: Meaningful Improvement in Median Overall Survival in Patients With Second-Line NSCLC Supports Advancing Bavituximab Into Phase III Development; Contract Manufacturing Revenue Tops $17 Million for Nine ...
BRISBANE, AUSTRALIA: Key US Patent Granted for HyACT Targeted Chemotherapy in Colon Cancer; Extends Monopoly Rights for HA-Irinotecan as Well as Additional Colon Cancer Chemotherapies
...
: The German clinical contract research organization (CRO), ICRC-Weyer GmbH, is extending their Medical Writing Services with specialized Pharmacovigilance Writing, a comprehensive solution for regulato ...
MANCHESTER, NH: PAZ320 Demonstrated 40 Percent Reduction of Post-Meal Blood Glucose Without Serious Adverse Events
...
: The Berlin-based clinical contract research organization (CRO) ICRC-Weyer GmbH is adapting a process of integrating medical review procedures into Pharmacovigilance risk management, a method that will ...
PARSIPPANY, NJ: CHAMPION PHOENIX Trial Meets Protocol-Specified Predefined Efficacy Endpoint; Intravenous Bolus and Infusion of Cangrelor Provided Statistically Significant Improvement in Ischemic Events at 48 Hours ...
BOSTON, MA: Accomplished Executive to Drive Strategies That Support Precision and Accuracy of Clinical Trial Data
...
: ICRC-Weyer GmbH, a clinical contract research organization (CRO) based in Berlin, Germany, has released its review of the year 2012, stating it has been a successful and exciting 12 months for everybo ...
TUSTIN, CA: Contract Manufacturing Revenue Expected to Exceed $18 Million for Fiscal Year 2013; Company Reaches Agreement With FDA on Pivotal Phase III Clinical Trial Design for Cotara; Multiple Bavituximab Clini ...
BOSTON, MA: WCC President Rick Walovitch to Present on Central Review for Trials With Subjective Endpoints at CBI Bio/Pharmaceutical Imaging Forum on December 11th
...
